Valuation: Verastem, Inc.

Market Cap 747M 667M 622M 564M 1.06B 71.19B 1.07B 7.44B 2.91B 36.88B 2.81B 2.74B 118B P/E 2026 *
-4.56x
P/E 2027 * -6.39x
Enterprise Value 789M 705M 657M 595M 1.12B 75.18B 1.13B 7.86B 3.08B 38.94B 2.96B 2.9B 125B EV / Sales 2026 *
6.8x
EV / Sales 2027 * 4.14x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
10-07 B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating MT
09-28 Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer CI
09-18 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
09-17 Wolfe Research Initiates Verastem at Outperform MT
09-14 RTW Biotech NAV rises 15% as public investments drive returns AN
09-08 Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers CI
08-11 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
08-07 Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million CI
08-06 Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-28 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer CI
07-22 Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer CI
07-07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
1 day-9.70%
1 week-6.88%
Current month-7.45%
1 month+1.78%
3 months+34.72%
6 months+40.30%
Current year-3.50%
1 week 7.44
Extreme 7.445
8.6
1 month 7.2
Extreme 7.195
8.64
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Financial Officer

-2,566 0.0042%
10/1/26 Sell

Chief Executive Officer

-44,121 0.0717%
9/21/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-9.70%-6.88%-13.07%-2.61% 747M
-0.32%-5.97%+50.26%+76.20% 70.65B
-1.99%-11.55%+4.84%+49.58% 51.22B
-1.32%-1.46%+7.39%+31.23% 48.04B
-0.58%-2.03%+31.54%+31.92% 43.16B
-2.84%-9.26%+290.63%+678.68% 41.57B
-0.38%-3.48%+9.05%+98.08% 39.84B
-0.39%-1.59%+8.69%+42.99% 30.87B
-2.66%-7.49%+35.37%+3.22% 27.53B
-7.13%-8.84%-12.79%-18.26% 24.08B
Average -2.73%-3.22%+41.19%+99.10% 37.77B
Weighted average by Cap. -1.62%-4.27%+49.99%+116.22%

Financials

2026 *2027 *
Net sales 116M 104M 96.63M 87.56M 165M 11.06B 166M 1.16B 452M 5.73B 436M 426M 18.38B 180M 161M 150M 136M 257M 17.19B 258M 1.8B 703M 8.9B 678M 663M 28.57B
Net income -166M -148M -138M -125M -236M -15.83B -238M -1.65B -648M -8.2B -624M -610M -26.31B -158M -141M -131M -119M -224M -15.03B -226M -1.57B -615M -7.78B -592M -579M -24.97B
Net Debt 41.9M 37.42M 34.89M 31.61M 59.58M 3.99B 60.01M 417M 163M 2.07B 157M 154M 6.63B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-10-13 US$7.450 -9.70% 3,387,917
26-10-12 US$8.250 -1.55% 3,582,508
26-10-09 US$8.380 +3.33% 2,970,338
26-10-08 US$8.110 -1.88% 3,051,551
26-10-07 US$8.265 +6.65% 3,928,558
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.250USD
Average target price
15.00USD
Spread / Average Target
+81.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock